Compare Amgen, Inc. (AMGN) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Total Bond Market Index Fund ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Vanguard Total Bond Market Index Fund ETF trades at $72.75. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BND | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $75.17 |
52-Week Low | $271.18 | $72.45 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BND trades at $72.77, down 0.08% on the day, with a bearish technical signal driven by moving averages. Recent news highlights its role as a core bond ETF for stability and income, with comparisons to peers like iShares IGIB focusing on yield and cost advantages. The fund's dividend history shows consistent payouts, supporting its appeal for income-focused investors amid market volatility.
The outlook for BND is cautious due to bearish technicals and interest rate risks, but its low-cost, diversified bond exposure offers defensive appeal. Key risks include duration sensitivity to Fed hikes, while institutional inflows signal confidence in fixed income. Investors should weigh yield stability against potential price declines if rates rise further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
